{"id":6198,"date":"2022-08-10T00:03:23","date_gmt":"2022-08-09T18:33:23","guid":{"rendered":"http:\/\/induspharma.in\/?p=6198"},"modified":"2022-09-10T12:54:27","modified_gmt":"2022-09-10T07:24:27","slug":"chlorpromazine-hydrochloride-injection","status":"publish","type":"post","link":"https:\/\/induspharma.in\/productslist\/chlorpromazine-hydrochloride-injection\/","title":{"rendered":"Chlorpromazine Hydrochloride Injection"},"content":{"rendered":"<p align=\"center\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Chlorpromazine Hydrochloride Injection USP 25mg\/ml<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>COMPOSITION<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Each ml contains:<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Chlorpromazine Hydrochloride USP 25mg<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Water for Injection USP q.s.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>CLINICAL PHARMACOLOGY<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\"><b>Pharmacodynamic properties<\/b><\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\"><b>Pharmacotherapeutic Group: <\/b><\/span><span style=\"font-size: xx-small;\">Antipsychotics,<\/span><span style=\"font-size: xx-small;\"><b> ATC Code:<\/b><\/span><span style=\"font-size: xx-small;\">N05A A01<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Chlorpromazine is a phenothiazine neuroleptic.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\"><b>Pharmacokinetic properties<\/b><\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Chlorpromazine is rapidly absorbed and widely distributed in the body. It is metabolised in the liver and excreted in the urine and in the bile. Although the plasma concentrations of Chlorpromazine decline rapidly the excretion of Chlorpromazine metabolites from the body is very slow. Chlorpromazine is highly bound to plasma proteins. It readily diffuses across the placental barrier and small quantities have been detected in breastmilk. Children require smaller dosages than adults.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>INDICATION AND USAGE<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Chlorpromazine is a phenothiazine neuroleptic. It is indicated in the following conditions:<\/span><\/span><\/p>\n<ul>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Schizophrenia, other psychoses (especially paranoid) mania and hypomania.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Anxiety, psychomotor agitation, excitement, violent or dangerously impulsive behaviour.Chlorpromazine is used as an adjunct in the short term treatment of these conditions.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Intractable hiccup.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Nausea and vomiting of terminal illness (where other drugs are not available).<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Childhood schizophrenia and autism.<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>CONTRA-INDICATION<\/b><\/span><\/span><\/p>\n<ul>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hypersensitivity to the active substance or to any of the excipients listed.<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Bone marrow depression<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Risk of angle-closure glaucoma<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Risk of urinary retention related to urethroprostatic disorders<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">History of agranylocytosis<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Dopaminergic antiparkinsonism agents<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Nursing mothers<\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Citalopram, escitalopram<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>DRUG INTERACTIONS<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Adrenaline must not be used in patients overdosed with Chlorpromazine.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Anticholinergic drugs may reduce the antipsychotic effect of Chlorpromazine and the mild anticholinergic effect of Chlorpromazine may be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">The action of some drugs may be opposed by Chlorpromazine; these include amphetamine, levodopa, clonidine, guanethidine and adrenaline.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Increases or decreases in the plasma concentrations of a number of drugs, e.g. propranolol Phenobarbital have been observed but were not of clinical significance.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Simultaneous administration of deferoxamine and prochlorperazine has been observed to induce a transient metabolic encephalopathy characterised by loss of consciousness for 48-72 hours. It is possible this may occur with Chlorpromazine since it shares many of the pharmacological properties of prochlorperazine.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">There is an increased risk of agranulocytosis when neuroleptics are used concurrently with drugs with myelosuppressive potential, such as carbamazepine or certain antibiotics and cytotoxics.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Combinations contraindicated<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Dopaminergics (quinaglide, cabergoline), not including dopaminergic antiparkinsonism agents, are contraindicated; reciprocal antagonism of the dopaminergic agent and neuroleptic.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Citalopram and escitalopram are contraindicated.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Combinations not recommended<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Dopaminergic antiparkinsonium agents (amantadine, bromocriptine, cabergoline, levodopa, lisuride, pergolide, piribedil, ropinirole) are not recommended: reciprocal antagonism of the antiparkinsonism agent and neuroleptic.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Neuroleptic-induced extrapyramidal syndrome should be treated with an anticholinergic rather than a dopaminergic antiparkinsonism agent (dopaminergic receptors blocked by neuroleptics).<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Levodopa: reciprocal antagonism of levodopa and the neuroleptic. In Parkinson&rsquo;s patients, it is recommended to use the minimal doses of each drug.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">QT prolonging drugs: There is an increased risk of arrhythmias when neuroleptics are used with concomitant QT prolonging drugs (including certain antiarrhythmics, antidepressants and other antipsychotics including sultopride) and drugs causing electrolyte imbalance.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Alcohol: alcohol potentiates the sedative effect of neuroleptics. Changes in alertness can make it dangerous to drive or operate machinery. Alcoholic beverages and medication containing alcohol should be avoided.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Lithium (high doses of neuroleptics): concomitant use can cause confusional syndrome, hypertonia and hyper-reflexivity, occasionally with a rapid increase in serum concentrations of lithium. There have been rare cases of neurotoxicity Lithium can interfere with the absorption of neuroleptic agents.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Combinations requiring precautions<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Anti-diabetic agents: concomitant administration of high chlorpromazine doses (100mg\/day) and anti-diabetic agents can lead to an increase in blood sugar levels (decreased insulin release). Forewarn the patient and advise increased self-monitoring of blood and urine levels. If necessary, adjust the anti-diabetic dosage during and after discontinuing neuroleptic treatment.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Topical gastrointestinal agents (magnesium, aluminium and calcium salts, oxides and hydroxides): decreased GI absorption of phenothiazine neuroleptics. Do not administer phenothiazine neuroleptics simultaneously with topical GI agents (administer more than 2 hours apart if possible).<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Combinations to be taken into consideration<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Antihypertensive agents: potentiation of the antihypertensive effect and risk of orthostatic hypotension (additive effects). Guanethidine has adverse clinically significant interactions documented.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Atropine and other atropine derivatives: imipramine, antidepressants, histamine H1-receptor antagonists, anticholinergic antiparkinsonism agents, atropinic antispasmodics, dispyramide: build-up of atropine-associated adverse effects such as urinary retention, constipation and dry mouth, heat stroke etc.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Other CNS depressants: morphine derivatives (analgesics, antitussives and substitution treatments), barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, hypnotics, sedative antidepressants, histamine H1 receptor antagonists, central antihypertensive agents increased central depression. Changes in alertness can make it dangerous to drive or operate machinery.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\"><b>WARNINGS AND PRECAUTIONS<\/b><\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">All patients must be advised that, if they experience fever, sore throat or any other infection, they should inform their physician immediately and undergo a complete blood count. Treatment will be discontinued if any marked changes (hyperleucocytosis, granulocytopenia) are observed in the latter.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">As agranulocytosis has been reported, regular monitoring of the complete blood count is recommended. The occurrence of unexplained infections or fever may be evidence of blood dyscrasia and requires immediate haematological investigation.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Neuroleptic malignant syndrome: treatment must be interrupted in the event of unexplained hyperpyrexia since this can be one of the signs of neuroleptic malignant syndrome (pallor, hyperthermia, autonomic dysfunction, altered consciousness, muscle rigidity). Signs of autonomic instability, such as hyperhydrosis and irregular blood pressure, can precede the onset of hyperthermia and as such constitute premonitory signs of this syndrome. While this neurolepticrelated effect can be of idiosyncratic origin, certain risk factors such as dehydration and brain damage would seem to indicate a predisposition.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Chlorpromazine should be avoided in patients with, hypothyroidism, phaeochromocytoma, myasthenia gravis and prostate hypertrophy. It should be avoided in patients known to be hypersensitive to phenothiazines or with a history of narrow angle glaucoma or agranulocytosis.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Acute withdrawal symptoms, including nausea, vomiting and insomnia, have very rarely been reported following the abrupt cessation of high doses of neuroleptics. Relapse may also occur, and the emergence of extrapyramidal reactions has been reported. Therefore, gradual withdrawal is advisable.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">In schizophrenia, the response to neuroleptic treatment may be delayed. If treatment is withdrawn, the recurrence of symptoms may not become apparent for some time.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Neuroleptic phenothiazines may potentiate QT interval prolongation which increases the risk of onset of serious ventricular arrhythmias of the torsade de pointes type, which is potentially fatal (sudden death). QT prolongation is exacerbated, in particular, in the presence of bradycardia, hypokalaemia, and congenital or acquired (i.e. drug induced) QT prolongation. If the clinical situation permits, medical and laboratory evaluations should be performed to rule out possible risk factors before initiating treatment with a neuroleptic agent and as deemed necessary during treatment.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Where clinically possible, the absence of any factors favouring the onset of ventricular arrhythmias should be ensured before administration:<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Bradycardia less than 55 beats per minute;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Hypokalemia;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Hypocalcaemia;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Hypomagnesaemia;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Starvation;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Alcohol abuse;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Concomitant therapy with other drugs known to prolong the QT interval;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Congenital long QT interval;<\/span><\/span><\/span><\/p>\n<p align=\"justify\">&bull; <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Ongoing treatment with any drug which could induce marked bradycardia (&lt;55 beats per minute), hypokalemia, intracardiac conduction depression or QT prolongation.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">With the exception of emergencies, it is recommended that the initial work up of patients receiving a neuroleptic should include and ECG.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Except under exceptional circumstances, this drug must not be administered to patients with Parkinson&rsquo;s disease.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">The concomitant use of chlorpromazine with lithium, other QT prolonging agents, and dopaminergic antiparkinsonium agents is not recommended.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">The onset of paralytic ileus, potentially indicated by abdominal bloating and pain, must be treated as an emergency.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Cases of venous thromboembolism (VTE), sometimes fatal have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Chlorpromazine and preventative measures undertaken.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Stroke: In randomised clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs or other populations of patients cannot be excluded. Chlorpromazine should be used with caution in patients with stroke risk factors.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Elderly Patients with Dementia: Elderly patients with dementia-related psychosis treated with antipsychotics drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g. , pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">As with all antipsychotic drugs, Chlorpromazine should not be used alone where depression is predominant. However, it may be combined with antidepressant therapy to treat those conditions in which depression and psychosis coexist.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Chlorpromazine is not licensed for the treatment of dementia-related behavioural disturbances.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Because of the risk of photosensitisation, patients should be advised to avoid exposure to direct sunlight.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">In those frequently handling preparations of phenothiazines, the greatest care must be taken to avoid contact of the drug with the skin.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Hyperglycaemia or intolerance to glucose has been reported in patients treated with Chlorpromazine. Patients with established diagnosis of diabetes mellitus or with risk factors for the development of diabetes who are started on Chlorpromazine, should get appropriate glycaemic monitoring during treatment.<\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">The following populations must be closely monitored after administration of chlorpromazine:<\/span><\/span><\/span><\/p>\n<ul>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Epileptics, since chlorpromazine may lower the seizure threshold. Treatment must be discontinued if seizures occur.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Elderly patients presenting with heightened susceptibility to orthostatic hypotension, sedation and extrapyramidal effects; chronic constipation (risk of paralytic ileus), and potentially prostatic hypertrophy. It should be used with caution particularly during very hot or cold weather (risk of hyper-, hypothermia<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Patients presenting with certain forms of cardiovascular disease, since this class of drug has quinidine&ndash;like effects can induce tachycardia and hypotension.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Patients with severe liver and\/or renal failure because of the risk of accumulation.<\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<ul>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Patients on long-term treatment should receive regular ophthalmological and haematological examinations.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Patients are strongly advised not to consume alcohol and alcohol-containing drugs throughout treatment.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Risk of allergic reaction including anaphylactic reactions and bronchospasm owing to the presence of sodium sulphite and disulfite in the formulation.<\/span><\/span><\/span><\/p>\n<\/li>\n<li>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\">Since there is a potential impact on cognitive function, children should undergo a yearly clinical examination to evaluate learning capacity. The dosage should be adjusted regularly as a function of the clinical status of the child.<\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\"><b>SIDE EFFECTS<\/b><\/span><\/span><\/span><\/p>\n<table width=\"100%\" cellspacing=\"1\" cellpadding=\"3\">\n<tbody>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">System Organ Class<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Very common<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">(&ge;1\/10)<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"26%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Common<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">(&ge;1\/100 to &lt;1\/10)<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Not known (cannot be estimated from available data)<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Blood and lymphatic system disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Agranulocytosis<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Leucopenia<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Immune system disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Systemic lupus erythematosus<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Antinuclear antibody positive<sup>1<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Bronchospasm<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Anaphylactic reactions<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Endocrine disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hyperprolactinaemia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Amenorrhoea<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Galactorrhoea<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Gynaecomastia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Erectile dysfunction<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Impotence<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Female sexual arousal disorder<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Metabolism and nutrition disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Weight increased<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"26%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Glucose tolerance impaired<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hyperglycaemia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hypertriglyceridaemia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hyponatraemia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Inappropriate antidiuretic hormone secretion<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Psychiatric disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Anxiety<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Lethargy<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Mood altered<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Nervous system disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Sedation<sup>2<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Somnolence<sup>2<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Dyskinesia (Acute dystonias or dyskenias, usually transitory are more common in children and young adults and usually occur within the first 4 days of treatment or after dosage increases.)<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Tardive dyskinesia<sup>3<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Extrapyramidal disorder<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Akathisia-often after large initial dose<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"26%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hypertonia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Convulsion<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Torticollis<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Oculogyric crisis<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Trismus<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Akinesia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hyperkinesia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Neuroleptic malignant Syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness)<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Parkinsonism (more common in adults and the elderly. It usually develops after weeks or months of treatment) to include tremor, rigidity or other features of Parkinsonism<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Eye disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Accommodation disorder<sup>4<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Deposit eye<sup>5<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Ocular changes<sup>7<\/sup><\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Cardiac disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">ECG changes include Electrocadiogram QT prolonged (as with other neuroleptics) , ST depression, U-Wave and T-Wave changes.<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Cardiac arrhythmias, including Ventricular arrhythmia and atrial arrhythmias, a-v block, Ventricular fibrillation<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Ventricular tachycardia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Torsade de pointes<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Cardiac arrests have been reported during neuroleptic phenothiazine therapy, possibly related to dosage.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Pre-existing cardiac disease, old age, hypokalaemia and concurrent tricyclic antidepressants may predispose.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Sudden death\/ Sudden cardiac death (with possible causes of cardiac origin as well as cases of unexplained sudden death, in patients receiving neurleptic phenothiazines)<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Vascular disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Orthostatic hypotension (Elderly or volume depleted subjects are particularly susceptible: it is more likely to occur after intramuscular administration).<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Embolism venous<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Pulmonary embolism (sometimes fatal)<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Deep vein thrombosis<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Respiratory, thoracic and mediastinal disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Respiratory depression<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Gastrointestinal disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Dry mouth<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Constipation<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Colitis ischaemic<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Ileus paralytic<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Intestinal perforation (sometimes fatal)<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Gastrointestinal necrosis (sometimes fatal)<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Necrotising colitis (sometimes fatal)<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Intestinal obstruction<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hepatobiliary disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Jaundice cholestatic<sup>6<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Liver Injury<sup>6<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Cholestatic liver injury<sup>6<\/sup><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Mixed liver injury<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Skin and subcutaneous tissue disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Dermatitis allergic<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Angioedema<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Contact skin sensitisation may occur rarely in those frequently handling preparations of chlorpromazine<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Skin rashes<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Urticaria<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Photosensitivity reaction<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Renal and urinary disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Urinary retention<sup>4<\/sup><\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Pregnancy, puerperium and Perinatal conditions<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Drug withdrawal syndrome neonatal<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Reproductive system and breast disorders<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Priapism<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"23%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">General disorders and administration site conditions<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"24%\"><\/td>\n<td style=\"background: transparent;\" width=\"26%\"><\/td>\n<td style=\"background: transparent;\" width=\"27%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Temperature regulation disorder<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Insomnia<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Agitation<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">1<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;may be seen without evidence of clinical disease<\/span><\/span><\/p>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">2<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;particularly at the start of treatment<\/span><\/span><\/p>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">3<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;particularly during long term treatment; may occur after the neuroleptic is withdrawn and resolve after reintroduction of treatment or if the dose is increased.<\/span><\/span><\/p>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">4<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;linked to anticholinergic effects<\/span><\/span><\/p>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">5<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;in the anterior segment of the eye caused by accumulation of the drug but generally without any impact on sight<\/span><\/span><\/p>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">6<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;A premonitory sign may be a sudden onset of fever after one to three weeks of treatment followed by the development of jaundice. Chlorpromazine jaundice has the biochemical and other characteristics of obstructive (cholestatic) jaundice and is associated with obstructions of the canaliculi by bile thrombi; the frequent presence of an accompanying eosinophilia indicates the allergic nature of this phenomenon. Liver injury, sometimes fatal, has been reported rarely in patients treated with chlorpromazine. Treatment should be withheld on the development of jaundice.<\/span><\/span><\/p>\n<p align=\"justify\"><sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">7<\/span><\/span><\/sup><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">&nbsp;The development of a metallic greyish-mauve coloration of exposed skin has been noted in some individuals, mainly females, who have received chlorpromazine continuously for long periods (four to eight years).<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Risk of allergic reactions including anaphylactic reactions and bronchospasm owing to the presence of sodium sulphite and disulfite in the formulation.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>EFFECTS ON ABILITY TO DRIVE AND USE MACHINES<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Drowsiness may occur during the initial days of treatment, therefore patients should be warned not to drive or operate machinery until these effects have ceased.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>OVERDOSE<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Toxicity and treatment of overdosage: Symptoms of chlorpromazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmia&rsquo;s, hypothermia, Parkinsonism, convulsions and coma. Severe extra-pyramidal dyskinesias may occur.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Treatment should be symptomatic with continuous respiratory and cardiac monitoring (risk of prolonged QT interval) until the patients conditions resolves.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Generalised vasodilation may result in circulatory collapse; raising the patient&rsquo;s legs may suffice. In severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstriction agents are not generally recommended; avoid the use of adrenaline.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life threatening, appropriate anti-arrhythmic therapy may be considered. Avoid lidocaine and, as far as possible, long acting anti-arrhythmic drugs.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions usually respond to procyclidine (5-10mg) or orphenadrine (20-40mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>DOSAGE &amp; MODE OF ADMINISTRATION<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><u>Posology:<\/u><\/span><\/span><\/p>\n<p><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Dosage of Chlorpromazine in:<\/b><\/span><\/span><\/p>\n<p><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Schizophrenia, other psychoses, anxiety, childhood schizophrenia and autism<\/span><\/span><\/p>\n<table width=\"100%\" cellspacing=\"1\" cellpadding=\"3\">\n<tbody>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"20%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Adult<\/b><\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"20%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Children under 1 year<\/b><\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"20%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Children 1-under 6 years<\/b><\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"20%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Children 6-12 years<\/b><\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"20%\">\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Elderly or debilitated patients<\/b><\/span><\/span><\/p>\n<\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Initially 25mg three time a day or 75mg at bedtime increasing the daily amounts of 25mg to an effective maintenance dose. This is usually between 75mg and 300mg daily, but some patients may require up to 1g per day.<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Do not use unless need is life saving.<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">0.5mg\/kg bodyweight every 4-6 hours to a maximum recommended dose of 40mg daily.<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\">\n<p align=\"center\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">1\/3 to &frac12; of adult dose \/to a maximum recommended daily dose of 75mg.<\/span><\/span><\/p>\n<\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Start with 1\/3 to &frac12; of the usual adult dose with a more gradual increase in dosage.<\/span><\/span><\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Hiccup<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">25 &ndash;50mg three times a day or four times a day<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">No information available<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">No information available<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">No information available<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">No information available<\/span><\/span><\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>NAUSEA AND VOMITING OF TERMINAL ILLNESS<\/b><\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><\/td>\n<\/tr>\n<tr valign=\"top\">\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">10-25mg every 4-6 hours<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Do not use unless need is life saving<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">0.5mg\/kg of bodyweight every 4-6 hours. Maximum daily dosage should not exceed 40mg<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">0.5mg\/kg of bodyweight every 4-6 hours. Maximum daily dose should not exceed 75mg.<\/span><\/span><\/td>\n<td style=\"background: transparent;\" width=\"20%\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Initially &#8531; to &frac12; the adult dose. The physician should then use his clinical judgement to obtain control.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>Method of administration<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">For oral administration. Initial dosage should be low and gradually increased until the optimal dosage for the patient is achieved. Patients should be under close supervision at the start of treatment until their optimal dosage has been reached. Individual patient dosage varies considerably and the optimum dosage may vary according to the formulation.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>PREGNANCY AND LACTATION<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><u>Pregnancy<\/u><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">There is inadequate evidence of the safety of Chlorpromazine in human pregnancy. There is evidence of harmful effects in animals. Like other drugs it should be avoided in pregnancy unless the physician considers it essential. It may occasionally prolong labour and at such a time should be withheld until the cervix is dilated 3-4 cm. Possible adverse effects on the foetus include lethargy or paradoxical hyperexcitability, tremor and low Apgar score.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">A large amount of exposure to chlorpromazine during pregnancy did not reveal any teratogenic effect.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">It is advised to keep an adequate maternal psychic balance during pregnancy in order to avoid decompensation. If a treatment is necessary to ensure this balance, the treatment should be started or continued at effective dose all through pregnancy.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Neonates exposed to antipsychotics (including Chrorpromazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and\/or withdrawal symptoms that may vary in severity and duration following delivery.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, bradycardia, tachycardia, feeding disorder, meconium ileus, delayed meconium passage, abdominal bloating. Consequently, newborns should be monitored carefully in order to plan appropriate treatment.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><u>Lactation<\/u><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Chlorpromazine may be excreted in milk, therefore breastfeeding should be suspended during treatment.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><u>Fertility<\/u><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">A decrease in fertility was observed in female animals treated with chlorpromazine. In male animals data are insufficient to assess fertility.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">In humans, because of the interaction with dopamine receptors, chlorpromazine may cause hyperprolactinaemia which can be associated with impaired fertility in women. In men, data on consequences of hyperprolactinaemia are insufficient with regard to fertility.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: medium;\"><span style=\"font-size: xx-small;\"><b>STORAGE CONDITION<\/b><\/span><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">Store in cool and dry place. Protected from light. <\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>KEEP OUT OF REACH OF CHILDREN<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>PRESENTATION<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><a name=\"_GoBack\"><\/a> <span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">5 Ampoules of 1ml\/2ml are kept in a tray.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">The tray containing 5 Ampoules and such 2 tray is kept in a unit carton along with a package insert.<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\"><b>MANUFACTURED IN INDIA<\/b><\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">INDUS PHARMA PRIVATE LIMITED<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">A 181, RIICO Ghiloth, Alwar, Rajasthan 301705<\/span><\/span><\/p>\n<p align=\"justify\"><span style=\"font-family: Times New Roman, serif;\"><span style=\"font-size: xx-small;\">A WHO GMP Certified Company<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chlorpromazine Hydrochloride Injection USP 25mg\/ml COMPOSITION Each ml contains: Chlorpromazine Hydrochloride USP 25mg Water for Injection USP q.s. CLINICAL PHARMACOLOGY Pharmacodynamic properties Pharmacotherapeutic Group: Antipsychotics, ATC Code:N05A A01 Chlorpromazine is a phenothiazine neuroleptic. Pharmacokinetic properties Chlorpromazine is rapidly absorbed and widely distributed in the body. It is metabolised in the liver and excreted in the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts\/6198"}],"collection":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/comments?post=6198"}],"version-history":[{"count":3,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts\/6198\/revisions"}],"predecessor-version":[{"id":6303,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/posts\/6198\/revisions\/6303"}],"wp:attachment":[{"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/media?parent=6198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/categories?post=6198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/induspharma.in\/productslist\/wp-json\/wp\/v2\/tags?post=6198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}